Highlights & Basics
- Acquired torticollis (cervical dystonia) is a rare, typically idiopathic, brain disorder causing involuntary neck movements.
- Often associated with pain.
- Patients may be able to relieve their symptoms by touching their neck, head, or face in a certain way (sensory trick).
- Targeted intramuscular injection of botulinum toxin is the therapy with the best proven efficacy. Oral medications and physical therapy may also have a role in the treatment of the condition.
- Treatment options for refractory acquired torticollis include deep brain stimulation, radiofrequency ablation, selective surgical denervation, chemical denervation, and intrathecal baclofen.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Citations
Stacy M. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin. 2008 May;26(suppl 1):23-42.[Abstract]
Singer C, Velickovic M. Cervical dystonia: etiology and pathophysiology. Neurol Clin. 2008 May;26(suppl 1):9-22.[Abstract]
Colosimo C, Suppa A, Fabbrini G, et al. Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol. 2010 Jul;17(suppl 1):15-21.[Abstract]
Rodrigues FB, Duarte GS, Marques RE, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2020 Nov 12;11:CD003633.[Abstract][Full Text]
Dashtipour K, Lew M. Cervical dystonia. In: Stacy MA, ed. Handbook of dystonia. New York, NY: Informa Healthcare; 2007:137-53.
Jankovic J, Leder S, Warner D, et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991 Jul;41(7):1088-91.[Abstract]
1. Stacy M. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin. 2008 May;26(suppl 1):23-42.[Abstract]
2. Marras C, Van den Eeden SK, Fross RD, et al. Minimum incidence of primary cervical dystonia in a multiethnic health care population. Neurology. 2007 Aug 14;69(7):676-80.[Abstract]
3. LaHue SC, Albers K, Goldman S, et al. Cervical dystonia incidence and diagnostic delay in a multiethnic population. Mov Disord. 2020 Mar;35(3):450-6.[Abstract][Full Text]
4. Papantonio AM, Beghi E, Fogli D, et al. Prevalence of primary focal or segmental dystonia in adults in the district of foggia, southern Italy: a service-based study. Neuroepidemiology. 2009;33(2):117-23.[Abstract]
5. Martino D, Aniello MS, Masi G, et al. Validity of family history data on primary adult-onset dystonia. Arch Neurol. 2004 Oct;61(10):1569-73.[Abstract][Full Text]
6. Defazio G, Aniello MS, Masi G, et al. Frequency of familial aggregation in primary adult-onset cranial cervical dystonia. Neurol Sci. 2003 Oct;24(3):168-9.[Abstract]
7. Chan J, Brin MF, Fahn S. Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991;6(2):119-26.[Abstract]
8. Singer C, Velickovic M. Cervical dystonia: etiology and pathophysiology. Neurol Clin. 2008 May;26(suppl 1):9-22.[Abstract]
9. Sun YV, Li C, Hui Q, et al. A multi-center genome-wide association study of cervical dystonia. Mov Disord. 2021 Dec;36(12):2795-801.[Abstract][Full Text]
10. Samii A, Pal PK, Schulzer M, et al. Post-traumatic cervical dystonia: a distinct entity? Can J Neurol Sci. 2000 Feb;27(1):55-9.[Abstract]
11. van Harten PN, Kahn RS. Tardive dystonia. Schizophr Bull. 1999;25(4):741-8.[Abstract][Full Text]
12. Delnooz CC, Pasman JW, Beckmann CF, et al. Altered striatal and pallidal connectivity in cervical dystonia. Brain Struct Funct. 2015 Jan;220(1):513-23.[Abstract]
13. Colosimo C, Suppa A, Fabbrini G, et al. Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol. 2010 Jul;17(suppl 1):15-21.[Abstract]
14. Pantano P, Totaro P, Fabbrini G, et al. A transverse and longitudinal MR imaging voxel-based morphometry study in patients with primary cervical dystonia. AJNR Am J Neuroradiol. 2011 Jan;32(1):81-4.[Abstract]
15. Werle RW, Takeda SY, Zonta MB, et al. The physical, social and emotional aspects are the most affected in the quality of life of the patients with cervical dystonia. Arq Neuropsiquiatr. 2014 Jun;72(6):405-10.[Abstract]
16. Muller J, Wissel J, Masuhr F, et al. Clinical characteristics of the geste antagoniste in cervical dystonia. J Neurol. 2001 Jun;248(6):478-82.[Abstract]
17. Jahanshahi M. Factors that ameliorate or aggravate spasmodic torticollis. J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):227-9.[Abstract][Full Text]
18. Albanese A, Asmus F, Bhatia KP, et al. EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol. 2011 Jan;18(1):5-18.[Abstract][Full Text]
19. Albanese A, Barnes MP, Bhatia KP, et al. A systematic review on the diagnosis and treatment of primary (idiopathic) dystonia and dystonia plus syndromes: report of an EFNS/MDS-ES Task Force. Eur J Neurol. 2006 May;13(5):433-44.[Abstract][Full Text]
20. De Pauw J, Van der Velden K, Meirte J, et al. The effectiveness of physiotherapy for cervical dystonia: a systematic literature review. J Neurol. 2014 Oct;261(10):1857-65.[Abstract][Full Text]
21. Delnooz CC, Horstink MW, Tijssen MA, van de Warrenburg BP. Paramedical treatment in primary dystonia: a systematic review. Mov Disord. 2009 Nov 15;24(15):2187-98.[Abstract]
22. Hu W, Rundle-Gonzalez V, Kulkarni SJ, et al. A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia. Parkinsonism Relat Disord. 2019 Jun;63:195-8.[Abstract][Full Text]
23. Duarte GS, Castelão M, Rodrigues FB, et al. Botulinum toxin type A versus botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016 Oct 26;(10):CD004314.[Abstract][Full Text]
24. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005 Nov 8;65(9):1423-9.[Abstract]
25. Camargo CH, Teive HA, Becker N, et al. Botulinum toxin type A and cervical dystonia: a seven-year follow-up. Arq Neuropsiquiatr. 2011 Oct;69(5):745-50.[Abstract][Full Text]
26. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache - report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2016 May 10;86(19):1818-26.[Abstract][Full Text]
27. Brans JW, Lindeboom R, Snoek JW, et al. Botulinum toxin versus trihexyphenidyl in cervical dystonia: a prospective, randomized, double-blind controlled trial. Neurology. 1996 Apr;46(4):1066-72.[Abstract]
28. Brashear A. Botulinum toxin type A in the treatment of patients with cervical dystonia. Biologics. 2009;3:1-7.[Abstract][Full Text]
29. Truong D, Duane DD, Jankovic J, et al. Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord. 2005 Jul;20(7):783-91.[Abstract]
30. Comella CL, Jankovic J, Truong DD, et al. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN(®), botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15;308(1-2):103-9.[Abstract]
31. Marques RE, Duarte GS, Rodrigues FB, et al. Botulinum toxin type B for cervical dystonia. Cochrane Database Syst Rev. 2016 May 13;(5):CD004315.[Abstract][Full Text]
32. Pappert EJ, Germanson T; Myobloc/Neurobloc European Cervical Dystonia Study Group. Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008 Mar 15;23(4):510-7.[Abstract]
33. Rodrigues FB, Duarte GS, Marques RE, et al. Botulinum toxin type A therapy for cervical dystonia. Cochrane Database Syst Rev. 2020 Nov 12;11:CD003633.[Abstract][Full Text]
34. Yi YG, Kim K, Yi Y, et al. Botulinum toxin type A injection for cervical dystonia in adults with dyskinetic cerebral palsy. Toxins (Basel). 2018 May 16;10(5):E203.[Abstract][Full Text]
35. Marsh WA, Monroe DM, Brin MF, et al. Systematic review and meta-analysis of the duration of clinical effect of onabotulinumtoxinA in cervical dystonia. BMC Neurol. 2014 Apr 27;14:91.[Abstract][Full Text]
36. Nijmeijer SW, Koelman JH, Kamphuis DJ, et al. Muscle selection for treatment of cervical dystonia with botulinum toxin-a systematic review. Parkinsonism Relat Disord. 2012 Jul;18(6):731-6.[Abstract]
37. Castagna A, Albanese A. Management of cervical dystonia with botulinum neurotoxins and EMG/ultrasound guidance. Neurol Clin Pract. 2019 Feb;9(1):64-73.[Abstract][Full Text]
38. Hong JS, Sathe GG, Niyonkuru C, et al. Elimination of dysphagia using ultrasound guidance for botulinum toxin injections in cervical dystonia. Muscle Nerve. 2012 Oct;46(4):535-9.[Abstract]
39. Swope D, Barbano R. Treatment recommendations and practical applications of botulinum toxin treatment of cervical dystonia. Neurol Clin. 2008 May;26(suppl 1):54-65.[Abstract]
40. Coleman C, Hubble J, Schwab J, et al. Immunoresistance in cervical dystonia patients after treatment with abobotulinumtoxinA. Int J Neurosci. 2012 Jul;122(7):358-62.[Abstract]
41. Tassorelli C, Mancini F, Balloni L, et al. Botulinum toxin and neuromotor rehabilitation: an integrated approach to idiopathic cervical dystonia. Mov Disord. 2006 Dec;21(12):2240-3.[Abstract]
42. Apkon SD, Cassidy D. Safety considerations in the use of botulinum toxins in children with cerebral palsy. PM R. 2010 Apr;2(4):282-4.[Abstract]
43. Kiss ZH, Doig-Beyaert K, Eliasziw M, et al. The Canadian multicentre study of deep brain stimulation for cervical dystonia. Brain. 2007 Nov;130(Pt 11):2879-86.[Abstract][Full Text]
44. Rodrigues FB, Duarte GS, Prescott D, et al. Deep brain stimulation for dystonia. Cochrane Database of Systematic Rev. 2019 Jan 10;(1):CD012405.[Full Text]
45. Volkmann J, Mueller J, Deuschl G, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: a randomised, sham-controlled trial. Lancet Neurol. 2014 Sep;13(9):875-84.[Abstract]
46. Cacciola F, Farah JO, Eldridge PR, et al. Bilateral deep brain stimulation for cervical dystonia: long-term outcome in a series of 10 patients. Neurosurgery. 2010 Oct;67(4):957-63.[Abstract]
47. Skogseid IM, Ramm-Pettersen J, Volkmann J, et al. Good long-term efficacy of pallidal stimulation in cervical dystonia: a prospective, observer-blinded study. Eur J Neurol. 2012 Apr;19(4):610-5.[Abstract]
48. Ostrem JL, Racine CA, Glass GA, et al. Subthalamic nucleus deep brain stimulation in primary cervical dystonia. Neurology. 2011 Mar 8;76(10):870-8.[Abstract]
49. Cohen-Gadol AA, Ahlskog JE, Matsumoto JY, et al. Selective peripheral denervation for the treatment of intractable spasmodic torticollis: experience with 168 patients at the Mayo Clinic. J Neurosurg. 2003 Jun;98(6):1247-54.[Abstract]
50. Wang J, Li J, Han L, et al. Selective peripheral denervation for the treatment of spasmodic torticollis: long-term follow-up results from 648 patients. Acta Neurochir (Wien). 2015 Mar;157(3):427-33; discussion 433.[Abstract]
51. Huh R, Han IB, Chung M, et al. Comparison of treatment results between selective peripheral denervation and deep brain stimulation in patients with cervical dystonia. Stereotact Funct Neurosurg. 2010;88(4):234-8.[Abstract]
52. Chung M, Han I, Chung SS, et al. Effectiveness of selective peripheral denervation in combination with pallidal deep brain stimulation for the treatment of cervical dystonia. Acta Neurochir (Wien). 2015 Mar;157(3):435-42.[Abstract]
53. Takeuchi N, Chuma T, Mano Y. Phenol block for cervical dystonia: effects and side effects. Arch Phys Med Rehabil. 2004 Jul;85(7):1117-20.[Abstract]
54. Lew MF, Brashear A, Factor S. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials. Neurology. 2000;55(12 suppl 5):S29-35.[Abstract]
55. Dashtipour K, Lew M. Cervical dystonia. In: Stacy MA, ed. Handbook of dystonia. New York, NY: Informa Healthcare; 2007:137-53.
56. Jahanshahi M, Marion MH, Marsden CD. Natural history of adult-onset idiopathic torticollis. Arch Neurol. 1990 May;47(5):548-52.[Abstract]
57. Camfield L, Ben-Shlomo Y, Warner TT. Impact of cervical dystonia on quality of life. Mov Disord. 2002 Jul;17(4):838-41.[Abstract]
58. Slawek J, Friedman A, Potulska A, et al. Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol. 2007 Apr-Jun;22(2):95-100.[Abstract]
59. Rinnerthaler M, Mueller J, Weichbold V, et al. Social stigmatization in patients with cranial and cervical dystonia. Mov Disord. 2006 Oct;21(10):1636-40.[Abstract]
60. Rondot P, Marchand MP, Dellatolas G. Spasmodic torticollis--review of 220 patients. Can J Neurol Sci. 1991 May;18(2):143-51.[Abstract]
61. Jankovic J, Leder S, Warner D, et al. Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991 Jul;41(7):1088-91.[Abstract]
62. Molho ES, Agarwal N, Regan K, et al. Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord. 2009 Jul 15;24(9):1384-7.[Abstract]
Key Articles
Other Online Resources
Referenced Articles
Sign in to access our clinical decision support tools